Lena Marth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lena Marth has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Johannes Levin
Department of Neurology, Ludwig-Maximilians-Universität München, Munich, Germany
4 shared publications Günter Höglinger
Department of Neurology, LMU University Hospital, LMU Medizin Ludwig‐Maximilians‐Universität München Munich Germany
3 shared publications- Olivia Wagemann
Department of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany
3 shared publications - Alexander Maximilian Bernhardt
Department of Neurology LMU University Hospital, Ludwig‐Maximilians‐Universität (LMU) München Munich Germany
2 shared publications - Andreas Hermann
Translational Neurodegeneration Section “Albrecht-Kossel”, Department of Neurology, University Medical Center Rostock, University of Rostock, 18147 Rostock, Germany
2 shared publications - Anja Schneider
Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn, Bonn, Germany
2 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (6) , e218494
Longitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome
Background and ObjectivesAdults with Down syndrome (DS) have an increased risk of developing early Alzheimer disease. While our previous cross-sectional study investigated the blood proteome in the...
- 22 September 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (6) , e218494
Open AccessLongitudinal Dynamics of the Blood Proteome Within the Alzheimer Spectrum in Down Syndrome
Background and ObjectivesAdults with Down syndrome (DS) have an increased risk of developing early Alzheimer disease. While our previous cross-sectional study investigated the blood proteome in the...
- Open Access
- 18 August 2026
- Published by Wiley in Journal of Intellectual Disability Research
Frailty in Adults With Down Syndrome: Cognitive, Functional and Biomarker Associations
Background: Down syndrome (DS) entails widespread age‐related functional decline affecting multiple organ systems, including genetically determined early‐onset Alzheimer disease (DSAD), resulting in an increased vulnerability to frailty early in life. We investigated the relationship between frailty, cognition and intellectual disability (ID) in adults with DS and explored biomarkers associated with frailty. Methods: This cross‐sectional study investigated 148 consecutive patients at a DSAD outpatient clinic. We applied correlation analyses and hierarchical linear models to determine associations of the Frailty Index for people with Intellectual Disabilities—short form (ID‐FI SF ) with measures of cognition (Cambridge cognitive assessment, CAMCOG‐DS), adaptive function (short adaptive behaviour scale, SABS), motor function (SPES/SCOPA), a screening tool (dementia screening questionnaire in individuals with intellectual disabilities, DSQIID‐G) for dementia‐related change in ADL (activities of daily living) performance, and ID severity (DSM‐5). Patients were stratified as cognitively healthy, DS‐MCI, DSAD dementia, secondary cognitive decline (CD) or CD of unknown cause. Exploratory analyses included blood biomarkers, bioimpedance measurements and indirect calorimetry. Results: Both baseline ID severity ( β = 0.093, p = 0.014) and cognitive performance (CAMCOG‐DS, β = −0.0033, p < 0.001) were independently associated with ID‐FI SF scores. Acquired cognitive decline was associated with (pre)frailty irrespective of aetiology. After adjustment for ID severity and cognition, ID‐FI SF scores were associated with adaptive function (SABS: β = −0.0033, p < 0.001), motor function (SPES‐SCOPA: β = 0.015, p < 0.001), change in ADL performance (DSQIID‐G: β = 0.0061, p < 0.001) and medication burden ( β = 0.016, p < 0.001). Exploratory biomarker analyses identified associations with ID‐FI SF scores for markers of neurodegeneration, inflammation, body composition, cardiac function and cellular stress signalling. Conclusions: Frailty in DS is associated with both ID severity and acquired cognitive decline. Future studies should determine whether severe baseline ID increases susceptibility to frailty or primarily influences frailty measurement through lower baseline functional abilities, potentially necessitating ID‐adapted frailty thresholds. Biomarker associations further support a multifactorial model of frailty involving neurodegeneration, inflammation and sarcopenia‐related processes.
- 18 August 2026
- Published by Wiley in Journal of Intellectual Disability Research
Open AccessFrailty in Adults With Down Syndrome: Cognitive, Functional and Biomarker Associations
Background: Down syndrome (DS) entails widespread age‐related functional decline affecting multiple organ systems, including genetically determined early‐onset Alzheimer disease (DSAD), resulting in an increased vulnerability to frailty early in life. We investigated the relationship between frailty, cognition and intellectual disability (ID) in adults with DS and explored biomarkers associated with frailty. Methods: This cross‐sectional study investigated 148 consecutive patients at a DSAD outpatient clinic. We applied correlation analyses and hierarchical linear models to determine associations of the Frailty Index for people with Intellectual Disabilities—short form (ID‐FI SF ) with measures of cognition (Cambridge cognitive assessment, CAMCOG‐DS), adaptive function (short adaptive behaviour scale, SABS), motor function (SPES/SCOPA), a screening tool (dementia screening questionnaire in individuals with intellectual disabilities, DSQIID‐G) for dementia‐related change in ADL (activities of daily living) performance, and ID severity (DSM‐5). Patients were stratified as cognitively healthy, DS‐MCI, DSAD dementia, secondary cognitive decline (CD) or CD of unknown cause. Exploratory analyses included blood biomarkers, bioimpedance measurements and indirect calorimetry. Results: Both baseline ID severity ( β = 0.093, p = 0.014) and cognitive performance (CAMCOG‐DS, β = −0.0033, p < 0.001) were independently associated with ID‐FI SF scores. Acquired cognitive decline was associated with (pre)frailty irrespective of aetiology. After adjustment for ID severity and cognition, ID‐FI SF scores were associated with adaptive function (SABS: β = −0.0033, p < 0.001), motor function (SPES‐SCOPA: β = 0.015, p < 0.001), change in ADL performance (DSQIID‐G: β = 0.0061, p < 0.001) and medication burden ( β = 0.016, p < 0.001). Exploratory biomarker analyses identified associations with ID‐FI SF scores for markers of neurodegeneration, inflammation, body composition, cardiac function and cellular stress signalling. Conclusions: Frailty in DS is associated with both ID severity and acquired cognitive decline. Future studies should determine whether severe baseline ID increases susceptibility to frailty or primarily influences frailty measurement through lower baseline functional abilities, potentially necessitating ID‐adapted frailty thresholds. Biomarker associations further support a multifactorial model of frailty involving neurodegeneration, inflammation and sarcopenia‐related processes.
- Open Access
- 24 June 2026
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 94 (09) , 340-350
Demenz mit Lewy-Körperchen
Zusammenfassung: Die Demenz mit Lewy-Körperchen (DLB) ist nach der Alzheimer-Demenz die zweithäufigste neurodegenerative Demenzform und zählt zu den atypischen Parkinson-Syndromen. Sie ist charakterisiert durch kognitive Fluktuationen, visuelle Halluzinationen, eine REM-Schlaf-Verhaltensstörung und Parkinson-Symptome. Typischerweise treten die kognitiven Einbußen vor oder bis maximal ein Jahr nach Beginn der motorischen Symptomatik auf („Einjahreskriterium“). Neuropathologisch liegt eine α-Synukleinopathie mit Lewy-Körperchen in Neuronen vor, häufig begleitet von Kopathologien. Die Diagnosestellung erfolgt klinisch nach den McKeith-Kriterien unter Einbeziehung z.B. bildgebender Biomarker. Therapeutisch stehen symptomorientierte Ansätze im Vordergrund. Krankheitsmodifizierende Therapien stehen bislang nicht zur Verfügung, werden jedoch in Therapiestudien erprobt. Die Entwicklung biologisch definierter Diagnosekriterien und molekularer Biomarker ist zentral für zukünftige Therapiestudien.
- 24 June 2026
- Published by Georg Thieme Verlag KG in Fortschritte der Neurologie · Psychiatrie
- Vol. 94 (09) , 340-350
Open AccessDemenz mit Lewy-Körperchen
Zusammenfassung: Die Demenz mit Lewy-Körperchen (DLB) ist nach der Alzheimer-Demenz die zweithäufigste neurodegenerative Demenzform und zählt zu den atypischen Parkinson-Syndromen. Sie ist charakterisiert durch kognitive Fluktuationen, visuelle Halluzinationen, eine REM-Schlaf-Verhaltensstörung und Parkinson-Symptome. Typischerweise treten die kognitiven Einbußen vor oder bis maximal ein Jahr nach Beginn der motorischen Symptomatik auf („Einjahreskriterium“). Neuropathologisch liegt eine α-Synukleinopathie mit Lewy-Körperchen in Neuronen vor, häufig begleitet von Kopathologien. Die Diagnosestellung erfolgt klinisch nach den McKeith-Kriterien unter Einbeziehung z.B. bildgebender Biomarker. Therapeutisch stehen symptomorientierte Ansätze im Vordergrund. Krankheitsmodifizierende Therapien stehen bislang nicht zur Verfügung, werden jedoch in Therapiestudien erprobt. Die Entwicklung biologisch definierter Diagnosekriterien und molekularer Biomarker ist zentral für zukünftige Therapiestudien.
- 11 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7)
Characterization of a novel homozygous CTSD variant causing adult-onset neuronal ceroid lipofuscinosis type 10: a case report
- 11 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7)
Characterization of a novel homozygous CTSD variant causing adult-onset neuronal ceroid lipofuscinosis type 10: a case report
- Open Access
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214510
Patterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia
Behavioral and neuropsychiatric symptoms are common in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). However, little is known about their patterns, time course, and association with brain atrophy. We, therefore, aimed to describe behavioral and neuropsychiatric phenotypes in patients with FTD and PPA, leveraging a hypothesis-free/data-driven approach. We included participants diagnosed with behavioral variant FTD (bvFTD) or PPA according to Rascovsky and Gorno-Tempini criteria from the German Center for Neurodegenerative Diseases Clinical Registry Study of Neurodegenerative Diseases-FTD prospective multicenter observational cohort study. Symptoms were assessed using the Neuropsychiatric Inventory-Questionnaire. Principal component analysis (PCA) was used to delineate symptom groups. Subsequently, frequency and severity across diagnostic groups were examined. We applied linear mixed-effects models to describe the longitudinal evolution of symptoms. Associations with MRI-assessed atrophy were investigated using linear regression models. A total of 314 patients (42.4% female, mean age 65.52 [SD 9.0] years) with bvFTD or PPA were included. MRI was available for 134 of 314 individuals. PCA revealed 4 natural symptom groups, labeled active behavioral, passive behavioral, affective, and psychotic phenotypes. Symptom groups were observed at comparable frequencies across diagnostic groups. Time from symptom onset (0.130 [0.044-0.217], p < 0.003), sex (1.376 [0.666-2.087], p < 0.001), and the interaction between the nonfluent variant of PPA and sex (-1.940 [-3.242 to -0.638], p = 0.004) showed a significant effect on the active behavioral phenotype, with symptom severity increasing over time and being most pronounced in men with bvFTD. Patients with bvFTD exhibited more severe passive behavioral symptoms compared with any other diagnostic group. For the affective phenotype, a significant interaction between time and sex (0.063 [0.010-0.117], p = 0.021) indicated a progressive increase in symptom severity in men over time. Furthermore, we found robust neuroanatomical correlations of passive behavioral symptoms with subcortical and bilateral frontal and cingulate cortical atrophy. Our findings demonstrate that behavioral and neuropsychiatric symptoms are prevalent in both bvFTD and PPA. Their severity depends on the disease duration, phenotypic group, and sex. This detailed understanding of symptomatology is crucial for optimizing patient care, diagnostic evaluations, and the design of clinical trials. Limitations comprise the lack of neuropathologic validation and the limited availability of MRI data.
- 24 February 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (4) , e214510
Open AccessPatterns and Trajectories of Behavioral and Neuropsychiatric Symptoms in Frontotemporal Dementia and Primary Progressive Aphasia
Behavioral and neuropsychiatric symptoms are common in frontotemporal dementia (FTD) and primary progressive aphasia (PPA). However, little is known about their patterns, time course, and association with brain atrophy. We, therefore, aimed to describe behavioral and neuropsychiatric phenotypes in patients with FTD and PPA, leveraging a hypothesis-free/data-driven approach. We included participants diagnosed with behavioral variant FTD (bvFTD) or PPA according to Rascovsky and Gorno-Tempini criteria from the German Center for Neurodegenerative Diseases Clinical Registry Study of Neurodegenerative Diseases-FTD prospective multicenter observational cohort study. Symptoms were assessed using the Neuropsychiatric Inventory-Questionnaire. Principal component analysis (PCA) was used to delineate symptom groups. Subsequently, frequency and severity across diagnostic groups were examined. We applied linear mixed-effects models to describe the longitudinal evolution of symptoms. Associations with MRI-assessed atrophy were investigated using linear regression models. A total of 314 patients (42.4% female, mean age 65.52 [SD 9.0] years) with bvFTD or PPA were included. MRI was available for 134 of 314 individuals. PCA revealed 4 natural symptom groups, labeled active behavioral, passive behavioral, affective, and psychotic phenotypes. Symptom groups were observed at comparable frequencies across diagnostic groups. Time from symptom onset (0.130 [0.044-0.217], p < 0.003), sex (1.376 [0.666-2.087], p < 0.001), and the interaction between the nonfluent variant of PPA and sex (-1.940 [-3.242 to -0.638], p = 0.004) showed a significant effect on the active behavioral phenotype, with symptom severity increasing over time and being most pronounced in men with bvFTD. Patients with bvFTD exhibited more severe passive behavioral symptoms compared with any other diagnostic group. For the affective phenotype, a significant interaction between time and sex (0.063 [0.010-0.117], p = 0.021) indicated a progressive increase in symptom severity in men over time. Furthermore, we found robust neuroanatomical correlations of passive behavioral symptoms with subcortical and bilateral frontal and cingulate cortical atrophy. Our findings demonstrate that behavioral and neuropsychiatric symptoms are prevalent in both bvFTD and PPA. Their severity depends on the disease duration, phenotypic group, and sex. This detailed understanding of symptomatology is crucial for optimizing patient care, diagnostic evaluations, and the design of clinical trials. Limitations comprise the lack of neuropathologic validation and the limited availability of MRI data.